Key facts
- This page summarizes Krista Fogarty's Form 4 filing for Lipocine Inc. (LPCN).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 19 Dec 2025, 17:07.
Krista Fogarty - 18 Dec 2025 Form 4 Insider Report for Lipocine Inc. (LPCN)
- Reporting relationship
- Principal Accounting Officer
- Issuer ticker
- LPCN
- Reported as of
- 18 Dec 2025
- Net transaction value
- +$87,301
- SEC form
- 4
- Accepted by SEC
- 19 Dec 2025, 17:07:29 UTC
- Prior SEC filing
- 30 Dec 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Krista Fogarty
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Krista Fogarty filed Form 4 for Lipocine Inc. (LPCN) on 19 Dec 2025.
Change
- Previous filing in this sequence was filed on 30 Dec 2024.
- Current net transaction value: +$87,301.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001906986
Primary reporting owner
Fogarty Krista
- Relationship
- Principal Accounting Officer
- Address
- 675 ARAPEEN DR SUITE 202, SALT LAKE CITY,
- Signature
- /s/ Krista Fogarty
- Signature date
- 19 Dec 2025
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LPCN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $87,301
- Shares
- +20,786
- Change %
- +107%
- Price
- $4.20
- Shares after
- 40,146
- Date
- 18 Dec 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 20,786
- Exercise price
- $4.20
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Subject to vesting whereby 1/3 of the shares subject to the award will vest on December 18, 2026, while the remaining 2/3 of the shares subject to the award will vest monthly on a prorated basis over the following two years.